Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PP 1493

Next Previous
Drug Profile

PP 1493

Alternative Names: PP-1493

Latest Information Update: 20 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pherecydes Pharma
  • Developer PHAXIAM Therapeutics
  • Class Anti-infectives; Antibacterials; Bacteriophages; Foot disorder therapies; Skin disorder therapies; Staphylococcus phages
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Bone and joint infections
  • Preclinical Diabetic foot ulcer

Most Recent Events

  • 13 Nov 2024 Preclinical development in Diabetic-foot-ulcer is ongoing in France (Topical, Drops)
  • 13 Nov 2024 PHAXIAM expects CTA clearance from European and UK (MHRA) regulatory authorities to initiate patient enrollment in Europe
  • 05 Nov 2024 PHAXIAM Therapeutics announces intention to submit IND to European Commission and Medicines and Healthcare products Regulatory Agency for Prosthetic infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top